Fundamental Analysis Discussion Only (IXC Thread), page-4

I also cant really find anything about the intracanical pressure for stroke unless its a foreign country looking into it. I just putting more emphasis on the fact that IIH is an encumbered market, we have no known competitors, we have the leading specialists in our team, like its a free run to glory I like to say and once there no one can take our market share. Its a big pharma buyout no doubt if successful.

$1 billion for IXC if successful as a buyout target is chum change for them. Im sure thats where Jason will come into affect. Anyway lets get there first